5 Best Compounder Stocks to Buy Now

4. Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with claims data reporting requirements introduced on February 1, Fierce Healthcare’s Dave Muoio reported. The move has drawn opposition from hospital groups and calls for federal regulators to intervene. In a June 1 letter to Thomas Engels, administrator of the Health Resources and Services Administration, Lilly said about 70%, or 2,350 distinct entities, have complied with the policy, and that it has sent two rounds of follow-up reminder letters to those that have not.

On June 2, 2026, Eli Lilly and Company (NYSE:LLY) announced presentation details for the European Hematology Association Annual Meeting, taking place June 11-14 in Stockholm, Sweden. Lilly will present results from the Phase 3 BRUIN CLL-322 study of Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, as part of a time-limited regimen for patients with previously treated chronic lymphocytic leukemia. Lilly also said Ajax Therapeutics and Kelonia Therapeutics, both pending proposed acquisitions, will present data at the meeting. Ajax will share first clinical results from the Phase 1 AJX-101 study of AJ1-11095 in myelofibrosis, while Kelonia will present additional correlative data from the Phase 1 inMMyCAR study of KLN-1010 in relapsed or refractory multiple myeloma.

Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products internationally.